SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DaiS who wrote (8560)5/26/1998 7:04:00 PM
From: VLAD  Read Replies (1) of 23519
 
DaiS,

A few things to consider:

weekly script total was about 15,000 before Viagra came out (month of March)

did you include milestone payments in total revenues?

As far as script numbers is concerned remember what Edderd said--often the first new script is for only one or two doses while the patient is getting titrated. Refill will usually be for those who are already titrated and would be for 6 doses. Total unit sales have much more meaning than script numbers. Most of the income will be from refills which have not been effected as badly as new scripts. Remember, refills are usually for 6 doses and new scripts are often for only 1 or 2 doses.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News